Literature DB >> 28694168

Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.

Guan Yang1, Bianca L Artiaga1, Sarah T Lewis1, John P Driver2.   

Abstract

CD1d-restricted invariant natural killer T (iNKT) cells are innate-like T cells that share phenotypic characteristics of both NK and conventional T cells (Tconv). Although iNKT cells have been well characterized in mice and humans, functional CD1d and CD1d-restricted iNKT cells are not universally expressed in mammals. Swine express iNKT cells that can be detected using α-galactosylceramide (α-GalCer)-loaded CD1d tetramers. In the present study, we characterized iNKT cells from the blood, spleen, lymph node, lung and liver of commercial mixed-breed pigs, and compared their phenotype to NK cells and Tconv. The principal findings are that pig iNKT cells are CD8α and CD44 positive and CD11b and Nkp46 negative. Most are also negative for the CD4 co-receptor, which is used to distinguish functionally distinct mouse and human iNKT cells subsets. The frequency of IFN-γ-producing CD8αbright iNKT cells was 3-4-fold higher than CD8αdull iNKT cells, suggesting that CD8α expression identifies iNKT cells with a unique functional role in immune responses. Finally, large variability was detected among pigs in interactions between iNKT cells and monocytes when iNKT cells were activated with α-GalCer, which raises a cautionary note about manipulating iNKT cells for immunotherapy. Collectively, our study provides important phenotypic and functional information about porcine iNKT cells that will be useful for understanding how iNKT cells contribute to immune responses in swine, with potential implications for human health.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; Subsets; Swine; iNKT cells; α-galactosylceramide

Mesh:

Substances:

Year:  2017        PMID: 28694168     DOI: 10.1016/j.dci.2017.07.006

Source DB:  PubMed          Journal:  Dev Comp Immunol        ISSN: 0145-305X            Impact factor:   3.636


  7 in total

1.  Next Generation Sequencing of the Pig αβ TCR Repertoire Identifies the Porcine Invariant NKT Cell Receptor.

Authors:  Guan Yang; Bianca L Artiaga; Carrie L Lomelino; Anitha D Jayaprakash; Ravi Sachidanandam; Robert Mckenna; John P Driver
Journal:  J Immunol       Date:  2019-02-18       Impact factor: 5.422

Review 2.  Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.

Authors:  Guan Yang; Jürgen A Richt; John P Driver
Journal:  Int J Mol Sci       Date:  2017-12-27       Impact factor: 5.923

3.  Porcine Invariant Natural Killer T Cells: Functional Profiling and Dynamics in Steady State and Viral Infections.

Authors:  Alexander Schäfer; Jane Hühr; Theresa Schwaiger; Anca Dorhoi; Thomas C Mettenleiter; Sandra Blome; Charlotte Schröder; Ulrike Blohm
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

4.  Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs.

Authors:  Bianca L Artiaga; Igor Morozov; Russell Ransburgh; Taeyong Kwon; Velmurugan Balaraman; Sabarish V Indran; Darling Melany De Carvalho Madrid; Weihong Gu; Jamie Henningson; Wenjun Ma; Jürgen A Richt; John P Driver
Journal:  Anim Dis       Date:  2022-08-01

Review 5.  The Role of Autophagy in iNKT Cell Development.

Authors:  Guan Yang; John P Driver; Luc Van Kaer
Journal:  Front Immunol       Date:  2018-11-14       Impact factor: 7.561

Review 6.  Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells.

Authors:  John P Driver; Darling Melany de Carvalho Madrid; Weihong Gu; Bianca L Artiaga; Jürgen A Richt
Journal:  Front Immunol       Date:  2020-10-20       Impact factor: 7.561

7.  Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide.

Authors:  Weihong Gu; Darling Melany D Madrid; Guan Yang; Bianca L Artiaga; Julia C Loeb; William L Castleman; Jürgen A Richt; John A Lednicky; John P Driver
Journal:  Dev Comp Immunol       Date:  2020-08-29       Impact factor: 3.636

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.